RWS Holdings PLC Completion of the acquisition of LUZ, Inc. (2323X)
February 17 2017 - 11:25AM
UK Regulatory
TIDMRWS
RNS Number : 2323X
RWS Holdings PLC
17 February 2017
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS NOT
FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY,
IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA,
AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND OR THE REPUBLIC
OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE
UNLAWFUL TO DO SO.
RWS Holdings plc
Completion of the acquisition of LUZ, Inc.
Further to the announcement of 14 February 2017, RWS Holdings
plc ("RWS") is pleased to announce today the completion of the
acquisition of 100% of LUZ, Inc. by RWS US Holding Co Inc., a
subsidiary of RWS.
Andrew Brode, Chairman of RWS, commented:
"We are delighted to have completed the acquisition of LUZ
which, together with CTi, will strengthen the Enlarged Group as a
leading player in the global Life Sciences translation space, with
a significant presence across North America, Europe and Asia.
"Following the acquisition, Life Sciences represent over 30% of
the Enlarged Group's revenues, with strong margins and further
opportunities for growth. The Life Sciences sector also provides
the potential for the Enlarged Group to develop and expand its
other services, especially in patent translation and foreign
filing.
"The acquisition of LUZ is an important element of our strategic
vision to deliver high quality, full-service global language
services across the value chain, and we are confident it will add
significant value to our shareholders."
For further information, contact:
RWS Holdings plc
Andrew Brode, Chairman 01753 480200
MHP
Katie Hunt / Simon Hockridge 0203 128 8100
Numis
Stuart Skinner / Kevin Cruickshank (Nominated Adviser) 0207 260
1000
Michael Burke (Corporate Broker)
About RWS:
RWS is a world leading provider of intellectual property support
services (patent translations, international patent filing
solutions and searches), a market leader in Life Sciences
translations and linguistic validation as well as a high level
specialist language service provider in other technical areas,
providing for the diverse needs of a blue-chip multinational client
base from Europe, North America and Asia. RWS is based in the UK,
with offices in Europe, the USA, (New York, East Hartford and
Chicago), China, Japan and Australia, and is listed on AIM, the
London Stock Exchange regulated market (RWS.L).
For further information, please visit: www.rws.com
Information on LUZ:
Based in San Francisco with c.100 employees, LUZ is a market
leading Life Sciences translation provider, specialising in medical
devices and regulatory activities. LUZ services a number of the
world's leading pharmaceutical and medical device manufacturers,
enjoying a preferred supplier relationship with certain customers.
The majority of LUZ's customers operate in highly regulated and
audited industries, and they place a premium on high quality
translations delivered to exacting deadlines. Services include
translation, desktop publishing, client review coordination, and
project management. The business' cloud-based AURORA translation
management platform allows fully integrated service provision and
seamless connectivity between suppliers and customers.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQGGUWPPUPMGQM
(END) Dow Jones Newswires
February 17, 2017 11:25 ET (16:25 GMT)
Rws (LSE:RWS)
Historical Stock Chart
From Apr 2024 to May 2024
Rws (LSE:RWS)
Historical Stock Chart
From May 2023 to May 2024